In new-onset atrial fibrillation with rapid ventricular response in ACS, what is first-line rate control if no contraindication?

Prepare for the Emergency Nursing Orientation 3.0 Cardiovascular Emergencies Test. Use interactive flashcards and detailed explanations with multiple choice questions. Enhance your understanding of cardiovascular emergencies and succeed on your exam!

Multiple Choice

In new-onset atrial fibrillation with rapid ventricular response in ACS, what is first-line rate control if no contraindication?

In new-onset atrial fibrillation with rapid ventricular response during an acute coronary syndrome, the priority is to slow the ventricular rate promptly to reduce myocardial oxygen demand and improve perfusion. The best first-line approach is IV rate-controlling therapy with either a beta-blocker (such as IV metoprolol) or a nondihydropyridine calcium channel blocker (such as IV diltiazem or verapamil) if there are no contraindications. These agents act quickly to slow AV nodal conduction and lower the heart rate, which helps stabilize the patient during ACS. IV lidocaine is for treating and suppressing ventricular arrhythmias, not for rate control in AF. Digoxin, especially oral, has a slow onset and is unreliable for acute rate control in the setting of RVR; it’s more of a later-add-on in specific contexts (e.g., in patients with chronic AF and heart failure, where rate control is needed but not acutely). The option that emphasizes rapid IV beta-blocker or IV nondihydropyridine calcium channel blocker with close monitoring for hypotension reflects the fastest, most effective way to achieve rate control acutely in this scenario, provided there are no contraindications such as hypotension, decompensated heart failure, bradycardia, or high-degree AV block.

In new-onset atrial fibrillation with rapid ventricular response during an acute coronary syndrome, the priority is to slow the ventricular rate promptly to reduce myocardial oxygen demand and improve perfusion. The best first-line approach is IV rate-controlling therapy with either a beta-blocker (such as IV metoprolol) or a nondihydropyridine calcium channel blocker (such as IV diltiazem or verapamil) if there are no contraindications. These agents act quickly to slow AV nodal conduction and lower the heart rate, which helps stabilize the patient during ACS.

IV lidocaine is for treating and suppressing ventricular arrhythmias, not for rate control in AF. Digoxin, especially oral, has a slow onset and is unreliable for acute rate control in the setting of RVR; it’s more of a later-add-on in specific contexts (e.g., in patients with chronic AF and heart failure, where rate control is needed but not acutely). The option that emphasizes rapid IV beta-blocker or IV nondihydropyridine calcium channel blocker with close monitoring for hypotension reflects the fastest, most effective way to achieve rate control acutely in this scenario, provided there are no contraindications such as hypotension, decompensated heart failure, bradycardia, or high-degree AV block.

More practice questions